Rochester, NY 7/11/2009 4:12:11 AM
AMGN - Rebecca M. Henderson, Ph.D., Appointed to Amgen's Board of Directors - Sourced WhisperFromWallStreet.com
Amgen Inc.
AMGN - Rebecca M. Henderson, Ph.D., Appointed to Amgen's Board of Directors - Sourced WhisperFromWallStreet.com
Amgen Inc.,AMGN
57.84 Up 0.03 (0.05%) 4:22PM ET
Amgen (NASDAQ: AMGN) announced today that its Board of Directors has appointed Rebecca M. Henderson, Ph.D., to the Company's Board. Dr. Henderson, 48, has recently joined the faculty at the Harvard Business School, having been the Eastman Kodak LFM Professor of Management at the Massachusetts Institute of Technology (MIT) Sloan School since 1999. She specializes in technology strategy and the broader strategic problems faced by firms in high technology industries. From 1995 to 1999, Dr. Henderson was a tenured associate professor at the MIT Sloan School. She has been a director of IDEXX Laboratories, Inc. since 2003. Dr. Henderson's appointment brings the number of Amgen Board members to 13. Dr. Henderson will serve as a member of the Corporate Responsibility and Compliance and Governance and Nominating Committees of the Board.
Last Trade: 57.81
Day's Range: 57.38 - 58.76
52wk Range: 44.96 - 66.51
Volume: 8,595,847
ABOUT
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa; a co-promotion agreement with Wyeth for marketing and selling of ENBREL; and Johnson & Johnson to commercialize recombinant human erythropoietin as a human therapeutic.
---
WhisperfromWallStreet.com has a proven track record in picking winning stocks. While neither we nor anyone can offer a guarantee, we scan countless stocks on a daily basis to seek out those that have the greatest opportunity for gain. When we find these stocks, we immediately send an alert to our membership. Please feel free to track our results by joining our newsletter free. So far in 2009 we have sent over 40 alerts to our members with an average gain of over 80%.
Join our stock alert service free.
If you're an investor and interested in knowing which penny stocks are getting ready to run, sign up for our penny alerts at http://whisperfromwallstreet.com/
During 2009 we have sent out over 40 stock alerts resulting in an over 80% price gain. Sign up now FREE to track our results.
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT NOTE: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This press release should not be construed as a solicitation to buy or sell any particular stock or security. Neither WhisperfromWallstreet, nor any of its affiliates are registered investment advisors or broker dealers.
